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Highlights –  
 Epilepsy in Intellectual Disability is managed by different professional groups 
 A common presentation is behaviour change related to epilepsy related drug changes 
 Little is known on how different groups approach concerns of challenging behaviour  
 Study examines training status, confidence and management practices across groups 
  There is considerable diagnostic overshadowing & need for training between groups 
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Abstract- 
 
Purpose: People with Intellectual Disability (ID) and epilepsy are more likely to experience 
psychiatric conditions, challenging behaviour (CB), treatment resistance and adverse effects 
of anti-seizure medications (ASM) than those without. This population receives care from 
various professionals, depending on local care pathways. This study evaluates the training 
status, confidence, reported assessment and management practices of different professional 
groups involved in caring for people with ID, epilepsy and CB.  
 
Methods: A cross sectional survey using a questionnaire developed by expert consensus 
which measured self-reported training status, confidence, and approaches to assessment 
and management of CB in people with ID and epilepsy was distributed to practitioners 
involved in epilepsy and/or ID.  
 
Results: Of the 83 respondents, the majority had either a psychiatry/ID (n = 39), or 
Neurology/epileptology background (n = 31). Psychiatry/ID and Neurology/epileptology had 
similar confidence in assessing CB in ID-epilepsy cases, but Psychiatry/ID exhibited higher 
self-rated confidence in the management of these cases. While assessing and managing 
CB, Psychiatry/ID appeared more likely to consider mental health aspects, while 
Neurology/epileptology typically focused on ASM.    
 
Conclusion: Psychiatry/ID and Neurology/epileptology professionals had varying training 
levels in epilepsy, ID and CB, had differing confidence levels in managing this patient 
population, and considered different factors when approaching assessment and 
management. As such, training opportunities in ID should be offered to neurology 
professionals, and vice versa. Based on the findings, a best practice checklist is presented, 
which aims to provide clinicians with a structured framework to consider causal explanations 
for CB in this population.  
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Epilepsy, anti-seizure medication, intellectual disability and challenging behaviour – 
Everyone’s business, no one’s priority 
 
Introduction 
 
Epilepsy is a chronic neurological disorder characterised by an enduring predisposition to 
recurrent seizures, with social, biological and psychological consequences [1]. Epilepsy is 
more prevalent in persons with intellectual disability (ID) [2], compared to the general 
population [3]. In a cross-sectional study of 14,751 patients with ID, 18.5% had epilepsy 
compared to 0.7% of controls (Prevalence ratio 25) [4]. 
There are challenges to effectively managing epilepsy in people with ID, including 
communication issues [5], increased risks of detrimental effects of antiepileptic treatment [6], 
a lack of evidence of the effectiveness of anti-seizure medications (ASMs) [7], 
neuropsychiatric comorbidity [8] and complexities assessing and managing challenging 
behaviour [9] [10]. These are difficult to individually quantify as they depend on the specific 
population and study methodology.  
Challenging behaviour is defined as culturally abnormal behaviours of an intensity, 
frequency or duration which jeopardise the safety of the individual or others, with possible 
resultant restricted access to the community [11]. Challenging behaviour is highly prevalent, 
with estimates suggesting 10% of ID patients having serious challenging behaviours 
Challenging behaviours have a complex relationship to epilepsy which can be affected by 
seizure type and medication related factors as well as other issues [10] [12] [13] [14,15]  
[16]. 
Comorbidities of epilepsy and ID include autistic spectrum disorder (ASD) and attention 
deficit hyperactivity disorder (ADHD). A meta-analysis has shown a pooled prevalence of 
epilepsy of 21.5% in persons with autism and intellectual disability v. 8% in autism without 
intellectual disability [17]. 
 
Care pathways for people with ID and epilepsy are fragmented, poorly defined, regulated 
and governed [18], with marked heterogeneity in service provision between different UK 
regions. The professional discipline with treatment responsibility (e.g. neurology vs. 
psychiatry led) [18], and the context care is provided can vary widely, e.g. the general 
neurology outpatient clinic (with or without input from an ID psychiatrist) [18] or primary 
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care).Relatedly, the training of ID psychiatrists in epilepsy and that of neurologists in ID is 
non-standardised. In the UK, psychiatric training includes the option to specialise in the 
Psychiatry of ID, qualifying the specialist as an ID psychiatrist. There is a lack of clarity on 
training standards, competency pathways and expected roles [18] and variability in the level 
of specialism. ID psychiatrists are offered training in epilepsy due to its increased prevalence 
in this patient group, yet may lack specialist knowledge pertaining to the diagnostic, 
investigation, and management aspects of seizures and the effects of ASMs [19, 20]. 
Similarly, neurologists/epileptologists may have no training in the ID-specific elements of 
epilepsy, such as communication needs, environmental, risk, or mental capacity 
assessments, or an understanding of mental health and challenging behaviour [21].  
 
It is hypothesised that different professional groups could have different priorities, insights, 
approaches, experiences, and biases regarding challenging behaviours. This has not been 
well explored in the ID and epilepsy context. The aims of this study were:  
1. To identify the level of training of healthcare professionals in the 
assessment/management of challenging behaviour in patients with ID and epilepsy. 
2. To assess confidence in assessment/management of challenging behaviour in patients 
with ID (without epilepsy) and epilepsy (without ID). 
3. To assess approaches in the assessment/management of challenging behaviour in 
patients with ID and co-occurring epilepsy. 
4. To develop a best practice checklist to guide professionals dealing with challenging 
behaviour in patients with ID and epilepsy. 
Method and Materials 
 
Measures and Survey Development 
 
The study employed a mixed methodology, including qualitative and quantitative elements. A 
12-item questionnaire (see supplementary information) was developed by RS, VC and MK 
alongside a consultation panel (comprising 11 national experts of 16 invited in either: 
epileptology, neurology, neuropsychiatry or ID; RTA, HA-L, MB, CC, JD, AH, MM, MR, HR, 
AR, MS). The survey was designed to take approximately 15 minutes to complete to 
facilitate a balance between ease of use and detailed information [22].  
 
Initially, six vignettes were developed, then evaluated by the expert panel of clinicians and 
an expert by experience. After considering the qualitative feedback, on level of 
comprehension and clinical utility, two vignettes were taken forward for this present survey. 
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Two final clinical vignettes (supplementary material) were presented within the survey. 
These vignettes were selected following development work with the expert panel.  
 
Participants were asked to indicate their confidence in the assessment and management of 
each scenario on a five-point Likert scale from 1 - Not at all confident, to 5 - Very confident. 
Respondents entered free text (qualitative) replies to indicate factors they would consider in 
their approach to assessment and management.  
 
Participants and Recruitment  
 
The survey was accessible via SurveyMonkey®, with a link distributed by email to the 
professional networks and bodies which represent the occupational groups involved in the 
care of people with ID, epilepsy and challenging behaviour, and representatives from these 
networks and bodies were asked to forward the survey to their membership. The sample 
population was therefore drawn from the membership of the International League against 
Epilepsy British Chapter (ILAE, approximately 800 members), Royal College of Psychiatrists 
Faculty of ID (n=332), Epilepsy Nurses Association (n=340), and the Association of British 
Neurologists (n=800). As potential respondents could be members of more than one 
organization the survey specified at the start that only one response is needed. 
Characteristics of non-responders were not available.  
 
Data Analysis  
 
Respondents (n=70) were separated into two groups for quantitative analysis; 
neurology/epilepsy background, and psychiatry/ID background. Both quantitative 
(categorical and ordinal) and qualitative data were collected in this survey. Descriptive 
statistics and Chi-squared analysis were employed. Regarding Aim 1 and 2, descriptive 
statistics and Chi-squared analysis was used to compare the psychiatry and neurology 
groups. Where the Likert scale (1-5) was analysed using Chi-square approach, the 
responses were divided into two groups. The two Likert points indicating confidence (very 
confident and partially confident) were grouped, and compared to the two Likert points 
indicating low confidence (very unconfident and partially unconfident). The 2x2 analysis 
incorporated psychiatry and neurology groups and compared confident and low confidence 
groups. 
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P value significance was initially set at <0.05, but with 11 hypotheses being tested, multiple 
comparisons were corrected with a Bonferroni correction and the newly determined 
significance level was set at P<0.0045.  
 
Aim three and aim four were approached using framework analysis, its methodology is 
appropriate for research that has specific questions, limited timeframe, pre-designed sample 
and a priori issues [23]. All respondents were included. Once key themes were assembled 
into a thematic framework, a checklist to provide a structured approach to causal 
explanations for challenging behaviour in this population was developed. The frequency of 
identified themes for different professional groups is presented.  
 
Ethics and Governance 
 
This project met the UK policy framework for health and social care research criteria for 
service evaluation, thus not requiring approval from a NHS Research Ethics Committee [24]. 
The survey was reviewed by each disseminating organization’s chair prior dissemination to 
their membership. The survey was anonymous, and did not record or store personal data. 
Consent was presumed by the return of a questionnaire by a participant.  
Results 
 
Eighty three responses were received, mainly from medical and nursing professionals (Table 
1). 95% were from the UK. Respondents were predominantly from a psychiatry/ID (n = 39) 
or a neurology/epilepsy background (n = 31) to include both medical and nursing disciplines. 
Respondents who did not indicate their specialism, and were classified as “unspecified” 
group (n = 13).  
 
Training of healthcare professionals in ID and epilepsy 
 
The majority of the respondents reported that they were fully qualified (e.g. Consultant 
Psychiatrist or Registered Learning Disability Nurse) (n = 65, 78%), with 10 (12%) currently 
in training and 8 (10%) did not specify their level of training. The cohort had 57 (69%) 
respondents with >10 years clinical experience.  
 
Sixty two (75%) respondents reported training/specialist interest/expertise in epilepsy and 44 
(53%) in challenging behaviour. Eleven (13%) stated that they had no specialist knowledge 
of either. Of the respondents, 20/39 (51%) Psychiatry/ID professionals considered 
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themselves to have expertise in both epilepsy and challenging behaviour, in contrast to 5/31 
(16%) Neurology/epileptology (Chi squared; two-tailed P value, 0.0005*) (Table 1).  
 
Healthcare professionals confidence in the assessment and management of challenging 
behaviour in patients with ID and epilepsy  
 
Background confidence 
 
Psychiatry and neurology professionals did not differ significantly in their confidence in the 
assessment [28 (74%) v 25 (81%) respectively] or management [30 (77%) v 18 (58%) 
respectively] of epilepsy associated with challenging behaviours (without co-occurring ID).  
 
For challenging behaviour in ID (without epilepsy) psychiatrist professionals when compared 
to neurology professionals rated themselves as more confident in the assessment [35 (90%) 
v 16 (51%) P=0.002*)] and management [13 (42%) of the Neurology/epileptology group 
(P=0.0001*)], the result was significantly different (see supplementary table). 
 
In their baseline confidence rating, psychiatry and neurology groups did show trends towards 
differences in their confidence in the assessment (28 v 19 respectively, P 0.051) and 
management (26 v 14 respectively, P, 0.016) of behavioural issues in epilepsy and co-
occurring ID. With psychiatry groups showing greater confidence which after Bonferroni 
correction did not show significance.  
 
The factors and approaches healthcare professionals consider when assessing and 
managing challenging behaviour in patients with ID and epilepsy (Vignettes) 
 
The framework analysis indicated four overarching themes, biological, 
psychological/psychiatric/behavioural (mental health factors), social and medication-related 
factors (table 2). Numerical results from summated themes per professional grouping are 
included in Table 3. Biological and social factors were considered equally between 
psychiatry and neurology groups, mental health factors were considered more frequently by 
psychiatry group and ASM related factors more frequently by neurology group (Table 3). 
Detailed statistical analysis for this aspect was not considered appropriate.  
Discussion 
 
 
This is the first UK based evaluation of healthcare professional’s approaches to those with 
epilepsy/ID and challenging behaviours. The findings highlight differences in training, levels 
of confidence, and in assessment and management of the same vignettes. 
[Type text] 
 
7 
 
Neurology/epileptology professionals report less training in ID or challenging behaviour, 
were less confident in this area and didn’t consider CB part of their skill set. They appeared 
more likely to attribute challenging behaviour to medication factors, in comparison to 
psychiatry colleagues who considered a broader range of factors, such as behavioural and 
psychiatric factors. Both groups considered biological and social factors to a similar extent.  
These findings are aligned with previous research which call for epileptologists to have 
enhanced psychiatric/behavioural neurology training [21, 25]. An ILAE survey of 211 
participants from 35 countries found >60% of adult neurologists self-rated their knowledge of 
neurodevelopmental disabilities (Attention Deficit Hyperactivity Disorder or Autism) as poor 
[21].  
 
The apparent focus of epilepsy specialists on the seizure disorder perhaps reflects historical 
factors [25], and has resulted in a recent call for epilepsy specialists to consider 
standardized assessments of patients with ID and to factor in their comorbidities  [26].  
 
Our study findings have themes relevant to; clinical practice, training, policy development, 
and future research.  
 
Implications for clinical practice  
 
This work confirms clinicians can consider the same scenario differently depending on 
multiple factors including their professional training, which will impact on care processes in 
this vulnerable patient group. Clinicians should be mindful that “expectations” they will act in 
a certain way does not make it necessarily the best option i.e. epileptologists alter ASMs.  
 
A standardised checklist (Table 2) which contains all factors a clinician should reasonably 
consider when facing challenging behaviour could reduce variation in practice. Clinicians 
should review their practice against peers by looking for their clinical “Achilles heel", for any 
cognitive bias [27]  in their training or their current clinical skills. “Anchoring bias”; and 
“premature closure” of diagnostic reasoning are pertinent in the evaluation of challenging 
behaviour to prevent diagnostic overshadowing.  
 
Clinical Training Implications 
 
Undergraduate and postgraduate curricula should consider the needs and deficiencies in 
training to date of various professional groups as identified in this study. The new ILAE 
epileptology curriculum rates skills in recognition and management of the needs of patients 
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with epilepsy and ID as an advanced proficiency [28]. Similarly, the role of ID psychiatrists in 
the management of epilepsy has recently been clarified using a gold/silver/bronze tiered 
competency framework (gold representing expert) [18]. The real world implementation is less 
clear, with a majority of ID psychiatrists being interested in working in epilepsy, but 
identifying the barriers of training, resources and time [19].  
 
Curriculum changes often target trainees, but measures to address the needs of working 
professionals are required. Professional development alongside multidisciplinary learning 
and working is key. Innovate methods of joint working and training between ID psychiatry 
and neurology urgently need to be considered and evaluated.  
 
Policy Implications 
 
A ILAE White Paper called for better care standards and pathways, multidisciplinary 
approaches, and improved links of relevant stakeholders to improve epilepsy care within ID 
settings [28].  Kerr et al [29] outlined an assessment framework by which patients with ID 
and epilepsy are considered from an epilepsy, medication, psychological and social 
perspective. The present work has built on this by assessing individual expert clinician’s 
training and confidence in these areas. The current study supports the need for multi-
disciplinary networks of clinicians and nurses from different speciality backgrounds. 
Appropriate local commissioning should be engaged for this purpose.  
 
Strengths and Limitations 
 
This is the first in-depth exploration of clinician’s training, confidence, and practice regarding 
the assessment and management of behavioural challenges in patients with epilepsy and ID. 
We obtained a sample of experienced UK professionals from a multi-disciplinary background 
with long service in their respective disciplines, which facilitated a focused examination of 
practice in this region. 
 
Regarding limitations, it is difficult to generalise the findings to other healthcare systems with 
different care pathways.  Varied factors can impact on confidence which were not evaluated, 
such as burn-out, workplace dynamics, expectations culturally about clinical skill are 
possessed by certain groups, and culture. These results are hypothesis generating.  There 
was incomplete information on non-responders, and a small sample size (perhaps as low as 
4%), for which the reason is unclear. Variable effort in completing the vignette free text 
answers is always possible.   
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It is perhaps the case that psychiatrists and neurologists don’t have such different 
approaches, but rather working in respective silos develop different approaches based on 
tradition and expectation. Neurologists given appropriate MDT access and time to resolve 
issues may have the same approach as psychiatry professionals. Access to MDT input, and 
the full clinical context, including the spectrum of severity of cases of ID seen was not 
assessed in this survey. Confidence is partly a culturally developed notion and may have 
other exogenous influences such as personality, burnout, wellbeing, political or workplace 
specific factors not assessed.  
 
Some psychiatrists reported expertise in epilepsy but not behavior and 8 reported expertise 
in neither. These responses were considered atypical, and it is unclear what the exact 
professional situations of these respondents were to provide further clarification.  
 
Research Implications 
 
Future research should assess the care pathways operational within the UK for this clinical 
population, as issues are likely to be particularly evident in geographical regions where care 
of those with ID and epilepsy is led solely by one professional discipline, with limited joint 
working. A future survey should examine the epilepsy/ID care provision region by region. 
This will provide an indication of the areas which could benefit from prioritisation of a 
strategy to develop multidisciplinary working between psychiatry/ID and 
neurology/epileptology professionals. The proposed checklist should be validated in future 
research. Little mention was made of ASD and ADHD and views of professionals could be 
the work of a future survey to see to what extent neurology specialists consider the 
diagnosis as influencing their decision making in epilepsy.  
 
Conclusion 
 
Differences in the training of psychiatry and neurology professionals and their clinical 
confidence may influence how challenging behaviours in ID and co-occurring epilepsy is 
approached.  
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Table 1: Professional disciplines of respondents.  
 
Professional discipline  N 
Nursing (n=28) ID specialist  9 
Nurse with expertise in epilepsy 10 
Unspecified 8 
ID and epilepsy nurse (included 
within psychiatry/ID group) 
1 
Medical/affiliated 
(n=55) 
Neurology 
based  
 
 
Neurology 14 
Epileptology 2 
Neurology/epileptology 5 
Psychiatry 
based  
 
 
 
 
 
 
ID psychiatry Gold [15] 8 
ID psychiatry Silver [15] 3 
ID psychiatry Bronze [15] 11 
ID psychiatry (other) 3 
Neuropsychiatry 2 
Neuropsychiatry/general psychiatry 1 
General psychiatry 1 
Others 
  
 
Clinical psychology 1 
General paediatrician  1 
General practitioner  
General practitioner with specialist 
interest in epilepsy 
1 
2 
Self-reported 
expertise in 
epilepsy and/or 
behavioural 
assessment 
Dual skilled 
(epilepsy and 
behavioural 
assessment) 
n (%) 
Behaviour 
alone 
n (%) 
Epilepsy alone 
n (%) 
No 
specialist 
training 
in either 
n (%) 
Psychiatry/ID 
(n=39)  
20 (51%) 9 (23%) 2 (5%) 8 (21%) 
Neurology/epilepsy  
(n=31) 
5 (16%) 0 (0%) 24 (77%) 2 (7%) 
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Table 2: Assessing and managing challenging behaviour in a person with ID and 
epilepsy: framework analysis and checklist 
 
Theme   
B
io
lo
g
ic
a
l 
fa
c
to
rs
 -
 h
is
to
ry
 t
a
k
in
g
, 
c
li
n
ic
a
l 
e
x
a
m
in
a
ti
o
n
 a
n
d
 p
h
y
s
ic
a
l 
in
v
e
s
ti
g
a
ti
o
n
s
 
 
 Explore the history of the presenting complaint (with a focus on antecedent factors, 
seizure severity, including brain injuries, cognitive changes).  
 Work out chronology of cause and effect. 
 Explore possible underlying physical aetiologies (general medical issues such as; 
infections, metabolic upset, speech and language assessment of swallow, gut health 
check including stool chart evaluation, gastrointestinal symptoms, feeding regime/appetite 
(including relationship to meals), pain assessment, dental assessment, sleep evaluation, 
neurodegenerative disease, review other co-morbidities, including a review for possible 
trauma/injury).  
 Complete biological investigations; blood testing (anti-seizure medication levels to assess 
compliance or toxicity), electroencephalography with comparison to previous 
electroencephalography results, video-telemetry, neuroimaging, lumbar puncture results, 
and video of any events/seizure diary.  
 Complete bowel charts and urine dipstick. 
 Measure weight (weight could be altering pharmacokinetics). 
 Assess analgesia needs.  
 Measure vital signs.  
M
e
n
ta
l 
h
e
a
lt
h
/p
s
y
c
h
o
lo
g
ic
a
l/
p
s
y
c
h
ia
tr
ic
/ 
b
e
h
a
v
io
u
ra
l 
fa
c
to
rs
 
 Complete a mental state examination/clinical psychology/ 
neuropsychiatry/neuropsychology assessment to explore for underlying/new psychiatric 
disorders such as depression, anxiety, autistic spectrum disorder, obsessive compulsive 
disorder).  
 Consider other factors, such as the patient’s insight into their behaviours and the impact it 
has on others,  
 Boredom/engagement/occupational therapy needs, forced normalisation, bereavement, 
sensory issues.  
 Complete a detailed behavioural assessment (e.g. positive behavioural support/functional 
analysis) with intellectual disability team.  
 Consider the need for positive behavioural support plan amendments, de-escalation 
strategies, anger management strategies and cognitive behavioural therapy.  
 Consider communication factors and refer for speech and language support if relevant.  
S
o
c
ia
l 
fa
c
to
rs
 
 Consider issues within social network, e.g. difficulties with friends or family. This will 
required detailed collateral history from other professionals and carers, particularly if the 
patient has communication difficulties.  
 Consider environmental or life circumstances changes, e.g. /routine/social 
situation/carers), quality of life, levels of independence, sexual issues, trauma, vocational 
and recreational needs, whether the current care package is adequate, evaluate the living 
situation, e.g. whether others in the residential environment are affecting the patient’s 
mental health.  
 Impact assessment of seizures on family and behaviour and provide family 
training/support to work with patient.  
 Consider the need for services such as outreach support or respite.  
 Consider the need for social worker involvement, as well as other professionals, such as 
buddying, assisted living, or key workers, etc.  
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M
e
d
ic
a
ti
o
n
 f
a
c
to
rs
 
 Consider relevance of any recent changes in the anti-seizure medication, or other 
medications. Trial small dose reductions in cases of possible forced normalisation.  
 Consider adverse effects including neuropsychiatric effects of medications.   
 Consider patient compliance with medication, factors such as medication brand change, 
polypharmacy, drug errors, interactions and contraindications. 
 Have rescue medications available. 
 Consider the patient’s level of understanding the risks and benefit analysis between drug 
side effects and the risk of having seizures.  
 Consider the efficacy of past therapeutic approaches.  
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Table 3: Themes endorsed by healthcare professionals in each vignette scenario  
 
 
Vignette 1 Vignette 2 
Assessment Treatment Assessment Treatment 
Neurology 
N (%) 
Psychiatr
y 
N (%) 
Neurolog
y 
N (%) 
Psychiatry 
N (%) 
Neurology 
N (%) 
Psychiatry 
N (%) 
Neurology 
N (%) 
Psychiatry 
N (%) 
 
Biological 8 (26) 17 (44) 10 (32) 16 (41) 28 (90) 36 (92) 24 (77) 
28 (72) 
 
Mental 
health 
16 (52) 28 (72) 16 (52) 26 (67) 9 (29) 14 (36) 8 (26) 
15 (38) 
 
Social 18 (58) 17 (44) 7 (23) 14 (36) 15 (48) 17 (44) 8 (26) 
11 (28) 
 
Medication 29 (94) 24 (62) 18 (58) 12 (31) 10 (32) 14 (36) 8 (26) 
8  (21) 
 
NB. For each vignette only one mention of a domain (such as biological) would be counted, 
giving a maximum of 31 for Neurology/epileptology and 39 for Psychiatry/ID. Two examples 
within the same domain were still only counted once. Note the absolute differences in 
Vignettes is not as relevant as is the difference between professional groups.  
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